• 855-853-4760
  • customerservice@arevapharma.com

Erlotinib

Erlotinib

The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.

Products Infomation
RX PRODUCT NDC# STRENGTH SIZE PRODUCT CLASS ADMINISTRATION CASE SIZE
Erlotinib 59923-725-30 25 mg 30 Antineoplastic Oral N.A
Erlotinib 59923-726-30 100 mg 30 Antineoplastic Oral N.A
Erlotinib 59923-727-30 150 mg 30 Antineoplastic Oral N.A
Wholesaler Erlotinib 25mg Erlotinib 100mg Erlotinib 150mg
AmerisourceBergen 10236033 10236032 10236031
Cardinal 5680640 5680657 5680665
McKesson 1573575 1573625 1573641